DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 93 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Divis Labs Share Price Live Updates: Divis Labs Trading Insights

Economic Times 4 hrs ago·12 Oct 2026, 3:05 am

Divis Laboratories is a leading global manufacturer of active pharmaceutical ingredients (APIs). The company is currently in the news due to its active participation in major industry events like the BIO International Convention. These events provide a platform for the firm to showcase its portfolio and engage with potential partners and customers.

For investors, this news is significant as it highlights the company's strong market position and its ongoing efforts to expand its global footprint. It signals the firm's commitment to innovation and growth within the competitive pharmaceutical sector. Keeping an eye on the company's future announcements and partnership developments will be key for those following its progress.